Regeneron, Sanofi: FDA Approves Dupixent To Treat Adult Patients With Bullous Pemphigoid June 20, 2025 — 01:41 am EDT Written by RTTNews.com for RTTNews -> ...

Regeneron Pharmaceuticals and Sanofi have won Food and Drug Administration priority review of their application seeking expanded approval of their blockbuster anti-inflammatory drug Dupixent for ...

Sanofi SNY and its partner, Regeneron REGN, announced that the FDA has approved their blockbuster medicine, Dupixent (dupilumab), for the treatment of adult patients with bullous pemphigoid (BP ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 20, ...

Regeneron Contacts: Media Relations Ilana Yellen Tel: +1 914-330-9618 [email protected] Sanofi Contacts: Media Relations Sandrine Guendoul ...

The acceptance of the Dupixent (dupilumab; Sanofi, Regeneron) application in this indication may give hope to the approximately 27,000 adults in the U.S. living with bullous pemphigoid (BP) that ...

Bullous pemphigoid is a chronic, relapsing skin disease with underlying type 2 inflammation. ... President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent.

Cite this: Trial Shows Dupilumab Reduces Itch, Disease Activity, Steroid Use in Bullous Pemphigoid - Medscape - March 13, 2025. Comments Commenting is limited to medical professionals.

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also ...